|
Mortimer, J E; Dehdashti, F; Siegel, B A et al. (2001) Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797-803
|
|
Dehdashti, F; Flanagan, F L; Mortimer, J E et al. (1999) Positron emission tomographic assessment of ""metabolic flare"" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51-6
|
|
Flanagan, F L; Dehdashti, F; Siegel, B A (1998) PET in breast cancer. Semin Nucl Med 28:290-302
|
|
Katzenellenbogen, J A; Welch, M J; Dehdashti, F (1997) The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17:1573-6
|
|
Mortimer, J E; Dehdashti, F; Siegel, B A et al. (1996) Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2:933-9
|
|
Dehdashti, F; Mortimer, J E; Siegel, B A et al. (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766-74
|
|
VanBrocklin, H F; Rocque, P A; Lee, H V et al. (1993) 16 beta-[18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. Life Sci 53:811-9
|
|
McGuire, A H; Dehdashti, F; Siegel, B A et al. (1991) Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32:1526-31
|
|
Dehdashti, F; McGuire, A H; Van Brocklin, H F et al. (1991) Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 32:1532-7
|
